Hydrochlorides of diphenyl propylamine possessing antianginal activity

专利摘要:
Diphenylpropylamine derivatives of the formula I …<IMAGE>… in which:… R<1> denotes hydrogen or methyl,… R<2> denotes hydrogen, methyl or n-decyl,… Z (a) denotes a phenyl group substituted by R<3>, R<4> and R<5>, in which:… R<3> denotes hydrogen, fluorine, chlorine or bromine, nitro, C1-12-alkyl, C1-4-alkoxy, phenoxy or benzyloxy,… R<4> and R<5> denotes hydrogen, chlorine, hydroxyl, alkoxy, benzyloxy, acetamido or carboxyl or… R<4> and R<5> together denote methylenedioxy or… (b) denotes 4-methoxynaphthyl or 4-ethoxynaphthyl, and R<6> denotes hydrogen or fluorine, with the proviso that R<1>, R<2>, R<3>, R<4>, R<5> and R<6> do not simultaneously denote hydrogen atoms,… and their physiologically tolerable acid addition salts are used as active substances in pharmaceutical agents which can primarily be advantageously used for the therapy of cardiac and circulatory disorders.
公开号:SU1588740A1
申请号:SU884355073
申请日:1988-01-25
公开日:1990-08-30
发明作者:Корбонитш Деже；Кишш Пал；Секереш Ласло；Папп Дьюла；Ковач Габор；Шанта Андрео；Вираг Шандор；Удвари Ева；Бата Имре；Мармароши Каталин；Тардош Ласло；Кермеци Петер；Гергели Вера；Варгаи Золтан
申请人:Хиноин Дьедьсер Еш Ведьесети Термекек Дьяра, Рт, (Инопредприятие)；
IPC主号:

专利说明:

The invention relates to novel compounds, derivatives of diphenylpropylamine, possessing antianginal activity.
The purpose of the invention is the detection in the series of difekilpropylamine derivatives of new compounds with higher antianginal activity.
Example 1. a. A mixture of 3,3-diphenyl-propylamine (84.5 g, 0.4 mol) and 3,4-dimethoxy-acetophenone- (72.1 g, 0.4 mol) is a detergent "
ten
five
under stirring for 10 hours at and under a pressure of 130-160 Pa, the resulting water is constantly distilled off. The mass of the solid that was solid after cooling of the crude N- (d-methyl-3,4-dimethoxybenzene1) -3, 3-diphenyl-propylamine is 149.5 g (theoretical yield). M.p. 98-102 ° C and increased by crystallization from ethanol to SW-Yub C.
b. To 1000 cm 3 of methanol suspension of the raw Schiff base obtained according to Example 1a, add with stirring over 40 minutes
sodium tetrahydroborate (37.8 g, 1.0 mol), then the mixture was stirred for 3 hours. The solvent was distilled off under reduced pressure; 800 ml of WATER are added to the residue, extracted three times with chloroform 152 ° C roform, taking 200 ml each time. The combined organic phases are evaporated, and by acidification with hydrochloric acid ethyl acetate to pH 1, salt is obtained. Thus, 145.0 g (88%) of 2- (3,4-dimethoxyphenyl) -6,6-diphenyl-3-azahexane-hydrochloride are obtained. . (I); R, R H, Z 3,4-dimethoxyphenyl, designation: KHL-8430 J. So pl. 171-i73 ° C (from aqueous ethanol),
C. A mixture of 112.04 g (0.3 mol) of recrystallized Schiff base 1- -v l prepared according to Example 1a. L
tox-acetophenone (18.0 g, Q, l mol 200 cm of ethanol and 2 g of 10% palladium on active carbon are hydrogenated under a pressure of 1.0 Mlla. After filtration, evaporation, salification with hydrochloric acid ethyl acetate and crystallization from ethanol are obtained 27 2 g (73%) KHL-8430 with a melting point of 17 -173 ° C.
e. Prepared from 2- (3,4-dimethoxyphenyl) -6,6-diphenyl-3-azahexane base prepared in accordance with Example 16 in ethanol with 1/2 mol-eq. 2 n. sulfuric acid sulphate melts at 195 ° C.
Well.T.pl.
z.t.pl.
The HBg salt is 176; the nitrate is 150.
and. M.p. 105-106 S.
j. A mixture of cooked sog (fine for example 1a of raw Schiff base, 1000 cm of ethanol and 4 g of Rene nickel are hydrogenated at atmospheric
thirty
vania, 500 cm ethanol and 11 G, 0% - „o-: 57 G T ° YY g palladium on active carbon hypoip 35 J -Dimethoxyphenyl) -1- (benzylamine pressure and at. After filtration, evaporation gives salt with hydrochloric acid ethyl acetate or hydrochloric acid ethanol, 145.0 g (88%) of KHL-8430 is obtained, which melts at 17i-173 c.
PRI mme R 2. a. A mixture of 28.0 g of 1-bromo-3,3-diphenylpropane, 27.1 g
 / eleven-
40
Palladium on active carbon is hydrogenated at 25 ° C and atmospheric pressure until the absorption of hydrogen ceases. After filtration and evaporation, the residue is acidified with 30 cm of hydrochloric acid (37%) up to pH, then the resulting salt is mixed with 140CM water. Thus, 119 g (96.3%) of KHL-8430 are obtained, m.p. 71 173 C.
g. A mixture of 3, 3-diphenyl-propylamine (21.1 g, 0.1 mol), 3,4-dimethoxy-acetophenone (18.0 g, 0.1 mol)
and 200 cm of xylene is heated with a water separator until the water separation ceases. The solvent is distilled off under reduced pressure, the remaining Schiff base (75 g) is hydrogenated with a mixture of 250 ml of ethanol and 2 g of 10% palladium on active carbon, according to example c. 5 31.5 g (84%) of KHL-8430 are obtained.
The mixture of 3, 3-diphenyl-propylamine (21.1 g, 0.1 mol), 3,4-dimeno) ethane, 15.0 g of potassium carbonate and 100 cm of dimethylformamide is stirred for 16 hours at. After filtration, the solvent is distilled off under reduced pressure, the residue is 100 cm of a solution of glacial acetic acid with 0.5 g of a catalyst based on platinum oxide and hydrogenated at a pressure of 0.4 Sh. After stopping the absorption of hydrogen (about 5 hours), it is diluted with 100 cm of methanol, filtered off and the solvent is distilled off. From the residue according to example GB, hydrochloride is obtained and crystallized from ethanol. Obtain 3.0 g of KHL-8430 with so pl. 171-173 C, which is identical to the compound obtained according to Example 1b.
b. A mixture of 18.1 g of 1- (3,4-dimethoxyphenyl) -1-a inostan, 10.6 g of benzaldehyde, 100 cm of methanol and 1 drop of pyridine is left to stand for 2 days at, then for 30 min. 3.8 g of sodium tetrahydroborate are added to the mixture and stirred in
0
152 ° C
tox-acetophenone (18.0 g, Q, l mol), 200 cm of ethanol and 2 g of 10% palladium on active carbon are hydrogenated under a pressure of 1.0 Mlla. After filtration, evaporation, salification with hydrochloric acid ethyl acetate and crystallization from ethanol, 27 2 g (73%) of KHL-8430 are obtained, m.p. 17 -173 ° C.
e. Prepared from a 2- (3,4-dimethoxyphenyl) -6,6-diphenyl-3-azahexane base prepared in accordance with Example 16 in ethanol with 1/2 mol-eq. 2 n. sulfuric acid sulphate melts at 195 ° C.
Well.T.pl.
z.t.pl.
The HBg salt is 176- nitrate, is 150152 ° C. Nicoginate is
and. M.p. 105-106 S.
j. A mixture of cooked sog (fine for example 1a of raw Schiff base, 1000 cm of ethanol and 4 g of Rene nickel are hydrogenated at atmospheric
0
: 57 G T ° HG 5 J -Dimethoxyphenyl) -1- (benzylamine pressure and at. After filtration, evaporation gives salt with ethyl acetate or hydrochloric acid ethanol. 145.0 g (88%) of KHL-8430 is obtained, which melts at 17i-173 c.
PRI mme R 2. a. A mixture of 28.0 g of 1-bromo-3,3-diphenylpropane, 27.1 g
 / eleven-
: 57 G T ° YY J -Dimethoxyphenyl) -1- (benzyl

but) -ethane, 15.0 g of potassium carbonate and 100 cm of dimethylformamide are stirred for 16 hours at. After filtration, the solvent is distilled off under reduced pressure, the residue is 100 cm of a solution of glacial acetic acid with 0.5 g of a catalyst based on platinum oxide and hydrogenated at a pressure of 0.4 Sh. After stopping the absorption of hydrogen (approximately 5 hours), it is diluted with 100 cm of methanol, filtered off and the solvent is distilled off. From the residue according to example GB, hydrochloride is obtained and crystallized from ethanol. Obtain 3.0 g of KHL-8430 with so pl. 171-173 C, which is identical to the compound obtained according to Example 1b.
b. A mixture of 18.1 g of 1- (3,4-dimethoxyphenyl) -1-a inostan, 10.6 g of benzaldehyde, 100 cm of methanol and 1 drop of pyridine is left to stand for 2 days at, then for 30 min. 3.8 g of sodium tetrahydroborate are added to the mixture and stirred in
for 3 hours. The solvent is distilled off, the residue is diluted with water, extracted with chloroform, dried and the chloroform is evaporated. The thus-obtained α-phenyl-3- (3,4-dimethoxyphenyl) -2-azabutane (27.1 g) can be directly used in the method described in Example 6.
Example 3. To a mixture of 18.1 g of 1- (3,4-dimethoxyphenyl) -1-aminoethane, 15 g of potassium carbonate and 100 cm of butanol, are added with stirring and heating for about an hour. A 50 cm butanol solution of 23.7 g of 1-chloro-3,3-dife, nilpropane and then heated until gassing stops. After cooling, it is filtered off, evaporated and prepared according to Example 16 28.5 g of KHL-8430, m.p. which is 171-173 0.
EXAMPLE 4 A mixture of 21.0 g of 1-amino-3,3-difle11Il-propane, 24.5 g of 1-bromo-1- (3,4-dimethoxyphenylethane), 15 g of potassium carbonate and 80 cm dimetha formamide is stirred for 15 at 50 ° C and filtered. The solvent was distilled off under reduced pressure, and the residue was treated with chloroform. After salt formation according to Example 16 and two times crystallization from aqueous ethanol, a yield is obtained. 24.0 g KHL-8430, m.p. which is 171-i73 ° C.
Example 5. 180 cm of an ethanol solution of 21.0 g of 3,3-diphenylpropionic aldehyde and 18.1 g of 1- (3,4-dimethoxyphenyl) -aminoethane are heated for 40 minutes, then the mixture after adding 2 cm of water at 33-35 ° C for 30 minutes are reacted with 4 g of sodium tetrahydroborate. After distilling off the alcohol, the residue is treated with water, extracted with chloroform and the chloroform solution is treated according to example 16.
30.0 g of KHL-8430 are obtained with a mp. 171-173 ° C (from aqueous ethanol).
Example K27, g 1-phenyl-3- (3,4-dimethoxyphenyl) -2-azabutane (prepared according to example 2b) in 80 cm of dimethylformamide at 70 ° C with stirring for 1 h was added dropwise 7.1 g of 2-chloroethanol. Stir for another 5 hours, then filter. The filtrate is evaporated, dissolved in 150 cm of chloroform and heated for 1 h with 20 cm of thionyl chloride (up to lp
0
0
five
five
gassing). The salt remaining after dissolving is dissolved in water, made basic with ice-cooling and extracted with ether. The ether solution is dried over sodium sulphate and filtered off. After distillation. e4ira is obtained in the form of an oil, which is formed from 1- (N- (1- (3,4-dimethoxyphensh1) -ethan-1-yl) -K-benzyl) -amnno-2-chloroethane,
16.5 g of this crude oil is dissolved in 100 cm of benzene and heated for 2 hours with stirring.
5 9.7 g of diphenylacetate and 2.5 g. sodium amide. After cooling, water is stirred in, the ash-free phase is separated, filtered and evaporated. The residue was dissolved in diethyl ether prepared using 1: 1-l-diphenyl-1-cyano-3- (N- (1 (3,4-dimethoxyphenyl) -ethan-1-yl) -N-benzyl) ethanol hydrochloride; -aminopropane hydrochloride is crystallized from ethanol. 10 g of the hydrochloride obtained in this way are dissolved in 100 cm of water, alkalinized with cooling, extracted with 100 cm of benzene, dried over sodium sulfate and filtered. The filtrate, together with 10.0 g of sodium amide, is heated with stirring for 2 hours, after cooling it is filtered and evaporated. The residue is dissolved in 50 cm of concentrated acetic acid.
5 and hydrogenated with 0.1 g of a catalyst based on platinum oxide at 70 ° C and a pressure of 0.4 MPa (approximately 5 hours). The mixture is diluted.
0
50
0
see methanol, filtered, you 5
0
soaring, salt is obtained by gentle heating with hydrochloric acid. After crystallization from aqueous ethanol, 6.2 g of KHL-8430 are obtained, which melts at 171-172 ° C.
Example 7. 15.1 g of 1-phenyl-1-hydroxy-3-aminopropane and 19.0 g of 3,4-dimethoxy-acetophenone are stirred for 16 hours at 80 ° C and a pressure of 130-160 Pa, then cooled, mixed with a mixture of 50 cm of methanol and 2 cm of water, and reacted with 3.5 g of sodium tetrahydroborate at 30–40 ° C for 2 hours. After distilling off the solvent, the residue is dissolved in 100 cm of ether and salt is made with ethanol. Thus, the resulting crude 1-phenyl-1-hydroxy-3- (N-1- (3,4-dimethoxyphenyl)
l an-1-nl) -aminopropan.porid suspension in 100 cm of benzene, 40 cm of thionyl chloride are added with stirring over 40 minutes, the suspension is stirred for another hour at 40 ° C. The mixture is evaporated using a water jet pump (the maximum is at) the residue is dissolved in 100 cm of benzene and is reacted at 55-60 ° C for 1 hour with aluminum chloride, then heated for 2 hours after heating. acid ice The benzene phase is separated and the benzene is washed with water. The combined aqueous phases are strongly alkalinized under ice-cooling, extracted with ether, the ether phase is dried over sodium sulfate. The salt is then obtained with the aid of hydrochloric acid. Thus, KHL-8430 melting at 172-173 ° C is obtained.
Example 8. To 15.8 g of base 25b, 6-triphenyl-3-azhexane (Fendeline), 5.9 g of 98-100% formic acid are added with cooling, then added to the resulting thick oil for 5 minutes 5.7 g of a 30% aqueous formaldehyde solution. The mixture is kept at 40 s until the beginning of the g &amp; chill, then the heating is stopped for 30 minutes. After that, the mixture is stirred for 12 hours at 80 ° C and evaporated, the residue is triturated with 100 cm of a 5% hydrochloric acid solution, heated for 10 minutes in a water bath, cooled during cooling. The base is extracted with chloroform, dried, filtered and ground, the residue is dissolved in ether and the salt is obtained with ether. 14.2 g of 3-methyl-2,6,6-triphenyl-3-azahexane hydrochloride are obtained, which melts at
96 C.

Example 9. A mixture of 30.0 g of 1,5,5-triphenyl-3-azapentane, 24.5 g of 1-bromo-1- (3,4-dimethoxyphenyl) - ethane, 15.0 g of potassium carbonate and 100 cm dimethylformamide is stirred for 16 h at. The mixture is filtered, the solvent is distilled off, the residue is distilled in 100 cm of acetic acid with 0.5 g of platinum oxide at 0.4 Pa and diluted. 100 cm of methanol and filtered, the solvent is distilled off. From the residue according to example 16, 30.0 g KHL are obtained.
ten
15
-
35
20
25
thirty
40
45
0
five
8430, which has a mp. 171-173 C (from aqueous ethanol).
Example 10. To a mixture of 21.0 g of 1.1 Diphenyl-3-amino-propane and 10.5 g of sodium bicarbonate for 30 hours, 30 cm of a butan solution of 24.5 g of 1-bromo-1- (3 , 4-dimethoxyfekyl) - ethane. The mixture is heated until gassing has ceased, the solvent is distilled off after cooling and filtration, and salt is obtained from the residue in an ethereal solution with hydrochloric ethanol. Three times crystallized from aqueous ethanol, get 18.0 g of KHL-8430, so pl. which 171-173 with.
Examples are 11-52. Using the methods described in Examples 1a and 1b and with the same yield, the compounds of general formula (I) listed in Table 1 can be obtained (R in each case is a hydrogen atom).
The proposed compounds have an anti-anginic effect. The effect of .2- (4-chlorophenyl) -6,6-diphenyl-3-aza-hexane hydrochloride in acute coronary insufficiency caused by vasopressin in rats is extremely strong. When administered intravenously 2 minutes before stimulating angina due to vasopressin, the ED for this compound is 0.054 mg / kg. Compared to this, the measured ED value of fendiline (a known structural analogue) under such conditions is 2.30 mg / kg. This compound is about 42 times more active than fendilin in these conditions.
Compounds of this type not only have a stronger and more prolonged anti-anginic effect, characteristic of fendiline, but also unexpectedly have other effects of a new type preferred in the treatment of heart disease. 2- (3,4 Dimethoxyphenyl) -6,6-difensh1-3-azahexane (denoted as the hydrochloride of this compound in the following KHL-8430) with vasopressin-induced sore throat in rats, respectively, caused by coronary vascular obstruction (coronary occlusion) and In dogs, fendilin exceeds the strength and duration of therapeutic action in dogs; in addition, it is also less toxic when administered intravenously and orally than a standard substance.
In the case of vasopressin-induced angina in rats, measured 2 minutes after intravenous administration and, correspondingly, 60 minutes after oral administration, anti-anginic activity, acute toxicity values measured by intravenous and oral values, therapeutic indices and relative indices of therapeutic indices in relation to KHL-8AZO and fendilin listed in table 2.
The compounds of general formula (I), in contrast to fendilin and other calcium antagonists, do not have a cardio-depressive effect, which is a preferred advantage of the proposed compounds.
I
The antianginal activity of the synthesized compounds is as follows: Example Antianginal
activity,
mg / kg i.V
.
wil
1.46
0.054
0.48
1.15
0.78
1.40
0.68 1.35
0.92
0.36
0.39
0.94
0.56
1.02
1.52
1.52
1.52
2.30
588740-10

权利要求:
Claims (1)
[1]
Invention Formula
G drochloride diphenylpropylamine formula
five /
(CH2) 2-NH-CH-Z
25
§ -1 NSHEC, - (,
35
E -OS2N5, 40
45
or R - CH J Z AIM
3
 possessing antianginal activity.
sixteen
H
-NO, HC1
197-198
17
(3- "n-С-СНз НС1
18N
- O-osNzS1194-196
19H
-OCjHjНС1
20H
Q-OCHj- HC1 208-209
21
H
-QHC1
wedge
22
H
±
23
H
CHjO
24
DOS,
SNZO
.m
22.7-228
186-188
HC1
HC1
HC1
HC1
160-162 215-220
186-188 187-188
39n
40 n
3-CHNSS1
236-238
HC1
226-227
H N
.L.i..i
 -I -INS1
OCjHs
H gVocHj HCi
CH,
-OSNzNS1
CH,
CH,
CH.
CH,
CH,
CH,
C1
UN,
-fi-ci
but
-OF
Ob.
CH.
52
Sgo N ,,
-about
HC1
HCi
HC1
five
I.
212-214 181-183
192-194
C1
HCI
228-229
UN,
HCI
F ci
B.
g
OCHj
si
Maleinov 141-143
acid
HCI200
Kalein's acid 124-126
HCI
HCI
HCI
HCI
217-218 213
140-142 98-101
Table

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1588740A1|1990-08-30|Hydrochlorides of diphenyl propylamine possessing antianginal activity

---

FI95694C|1996-03-11|Substituted pyrimidine derivatives, process for their preparation and their use as intermediates

---

SU820659A3|1981-04-07|Method of preparing 4-amino-5-alkylsulfonyl-o-anisamide derivatives,their salts,oxides,left-and right-rotational isomers |

---

US3689524A|1972-09-05|Phenethylamine derivatives

---

DE3211676A1|1983-10-06|NEW DERIVATIVES OF CYCLOALKA | PYRROL CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF AND NEW CYCLOALKA | PYRROL CARBONIC ACIDS AS THE INTERMEDIATE LEVELS AND METHODS

---

DD232698A5|1986-02-05|PROCESS FOR PREPARING 2-AMINO-5-HYDROXY-4-METHYL-PYRIMIDINE DERIVATIVES

---

IE48368B1|1984-12-26|Imidazole derivatives

---

FR2630328A1|1989-10-27|HISTAMINE DERIVATIVE, ITS PREPARATION AND ITS THERAPEUTIC APPLICATION

---

JP2656594B2|1997-09-24|Diamine compound, process for producing the same, and medicament containing the compound for treating hypertension and inflammation

---

DE3114239C2|1986-04-03|N → 4 → -carbamoylpiperazine propanol derivatives, process for their preparation and pharmaceutical agent

---

US4602041A|1986-07-22|Benzylideneamino- and phenylacetylguanidines and their pharmaceutical uses

---

US4134991A|1979-01-16|Derivatives of 2-|-acetic acid

---

DE2059985C3|1979-10-04|Right-handed, basic substituted phenylacetonitriles, processes for their preparation and pharmaceuticals containing these compounds

---

EP0301936B1|1992-12-16|Piperidine derivatives, their preparation and their therapeutical use

---

SU812174A3|1981-03-07|Method of preparing cis-4a-phenyloctahydro-1h-2-pyrindine derivatives or their sal lts

---

US4645778A|1987-02-24|2-|-3-isobutoxy-n-substituted-phenyl-n-benzyl-propylamines, their preparation and pharmaceutical use

---

DE3014813A1|1980-11-13|2-HYDROXY-5- | BENZOESIC ACID DERIVATIVES

---

US4775673A|1988-10-04|Substituted acylpiperazinoquinazolines and pharmaceutical compositions containing same

---

US3657229A|1972-04-18|1 3-diaza-2 3-cycloalkene derivatives

---

RU2178786C2|2002-01-27|Derivatives of 4-|-benzoic acid, method of their synthesis and pharmaceutical composition

---

DE3817374A1|1988-12-01|2H-1-BENZAZEPIN-2-ON DERIVATIVES, PRODUCTION AND USE AS MEDICINAL PRODUCTS

---

EP1023287B1|2002-06-12|3-oxo-2|-1,2,4-triazine derivatives as ligands of 5ht1a receptors

---

WO1992011234A1|1992-07-09|Novel amines, process for producing them and medicaments containing said compounds

---

US4271193A|1981-06-02|N1-Benzoyl-N2-phenyldiaminopropanols and pharmaceutical compositions thereof, and processes for their preparation

---

US4360680A|1982-11-23|Therapeutically active 3-amino-1-phenyl and substituted phenyl-2-pyrazolines

同族专利:

---

公开号 | 公开日

---

IL83044A|1991-09-16|

---

PT85304A|1987-08-01|

---

FI873069A0|1987-07-10|

---

KR880001573A|1988-04-25|

---

CA1335104C|1995-04-04|

---

NO167658C|1991-11-27|

---

DK360187D0|1987-07-10|

---

IE60028B1|1994-05-18|

---

DE3778770D1|1992-06-11|

---

EP0253327A2|1988-01-20|

---

HUT46651A|1988-11-28|

---

NO872880L|1988-01-12|

---

CS271343B2|1990-09-12|

---

AU599117B2|1990-07-12|

---

FI873069A|1988-01-12|

---

IE871866L|1988-01-11|

---

ES2032778T3|1993-03-01|

---

YU129987A|1988-06-30|

---

AU7552687A|1988-01-14|

---

PT85304B|1990-03-30|

---

HRP930508A2|1995-02-28|

---

HU200591B|1990-07-28|

---

NZ221036A|1990-05-28|

---

KR910000864B1|1991-02-11|

---

AT75722T|1992-05-15|

---

NO167658B|1991-08-19|

---

SU1597096A3|1990-09-30|

---

CN1019571B|1992-12-23|

---

YU46559B|1993-11-16|

---

GR3004518T3|1993-04-28|

---

DD263980A5|1989-01-18|

---

SI8711299A8|1996-08-31|

---

FI95128C|1995-12-27|

---

CN87104753A|1988-06-15|

---

PL266759A1|1988-09-01|

---

DK360187A|1988-01-12|

---

FI95128B|1995-09-15|

---

CS511987A2|1989-08-14|

---

JPS6372657A|1988-04-02|

---

US4988730A|1991-01-29|

---

PH24514A|1990-07-18|

---

ZA874812B|1988-10-26|

---

JP2637737B2|1997-08-06|

---

EP0253327A3|1988-11-30|

---

EP0253327B1|1992-05-06|

---

PL150887B1|1990-07-31|

---

IL83044D0|1987-12-31|

---

NO872880D0|1987-07-10|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

CH462189A|1961-08-10|1968-09-15|Chinoin Gyogyszer Es Vegyeszet|Process for the preparation of substituted propylamine derivatives|

---

DE1171930B|1961-08-10|1964-06-11|Chinoin Gyogyszer Es Vegyeszet|Process for the preparation of substituted propylamine derivatives with coronary dilation activity|

---

GB1032650A|1962-05-24|1966-06-15|Chinoin Gyogyszer Es Vegyeszet|Improvements in or relating to diphenyl-propylamine derivatives|

---

DD122967A1|1975-07-10|1976-11-12|Lothar Luecke|HYLAMIN DERIVATIVES|IT1205124B|1987-06-05|1989-03-15|Simens Soteta Italiana Medicin|ACTIVE COMPOUND IN CARCIOVASCULAR THERAPY|

---

GB8823203D0|1988-10-04|1988-11-09|Pfizer Ltd|Therapeutic agents|

---

JPH04329415A|1991-04-30|1992-11-18|Fujitsu Ltd|Card type input/output interface device|

---

US5688938A|1991-08-23|1997-11-18|The Brigham & Women's Hospital, Inc.|Calcium receptor-active molecules|

---

US6001884A|1991-08-23|1999-12-14|Nps Pharmaceuticals, Inc.|Calcium receptor-active molecules|

---

US6031003A|1991-08-23|2000-02-29|Nps Pharmaceuticals, Inc.|Calcium receptor-active molecules|

---

DE122005000033I1|1994-10-21|2005-09-29|Nps Pharma Inc|Calcium receptor active compounds.|

---

US5858684A|1991-08-23|1999-01-12|The Brigham And Women's Hospital, Inc.|Method of screening calcium receptor-active molecules|

---

US5763569A|1991-08-23|1998-06-09|The Brigham And Women's Hospital, Inc|Calcium receptor-active molecules|

---

US6313146B1|1991-08-23|2001-11-06|Nps Pharmaceuticals, Inc.|Calcium receptor-active molecules|

---

KR100251995B1|1991-08-23|2000-06-01|젠센 제임스 유.|Calcium receptor active molecules|

---

US6011068A|1991-08-23|2000-01-04|Nps Pharmaceuticals, Inc.|Calcium receptor-active molecules|

---

US5962314A|1993-02-23|1999-10-05|Nps Pharmaceuticals, Inc.|Calcium receptor-active molecules|

---

US5198548A|1992-01-30|1993-03-30|Warner-Lambert Company|Process for the preparation of D and L-3,3-diphenylalanine and D and L-substituted 3,3-diphenylalanines and derivatives thereof|

---

US6071970A|1993-02-08|2000-06-06|Nps Pharmaceuticals, Inc.|Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases|

---

AT267009T|1993-02-23|2004-06-15|Brigham & Womens Hospital|CALCIUM RECEPTOR ACTIVE MOLECULES|

---

US5492933A|1993-10-08|1996-02-20|Sepracor, Inc.|Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof|

---

DK0907631T3|1996-05-01|2003-09-22|Nps Pharma Inc|Inorganic ion receptor active compounds|

---

SE9701144D0|1997-03-27|1997-03-27|Pharmacia & Upjohn Ab|Novel compounds, their use and preparation|

---

US6124507A|1997-12-10|2000-09-26|Union Carbide Chemicals & Plastics Technology Corporation|Electron donors|

---

EP0957073A1|1998-05-12|1999-11-17|Schwarz Pharma Ag|Novel derivatives of 3,3-diphenylpropylamines|

---

DE10315917A1|2003-04-08|2004-11-18|Schwarz Pharma Ag|Highly pure bases of 3,3-diphenylpropylamine monoesters|

---

FR2902789A1|2006-06-21|2007-12-28|Genfit Sa|SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

HU862873A|HU200591B|1986-07-11|1986-07-11|Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds|

---